CPT-11 (Irinotecan) in the Treatment of Colorectal Cancer: A new Mechanism of Action for Additional Activity

Abigerges D. , Armand J.P. , Chabot G.G. , Da Costa L. , Fadel E. , Cote C. , Hérait P. , Gandia D. : Irinotecan (CPT-11) high–dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl. Cancer Inst., 86: 446–449, 1994.

Bugat R. : CPT-11 in the treatment of colorectal cancer (CRC): safety profile. 5th International Congress of Anti-Cancer Chemotherapy, Paris, France. Jan/Feb 31-3 1995: S778.

Conti J.A. , Kemeny N. , Saltz L. , Tong W. , Chou T.C. , Pullian M. : Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC). 30th Annual Meeting of Am. Soc. Clin. Oncol., Dallas, Texas. May 14–17, 1994: 565.

Creemers G.J. , Lund B. , Verweij J. : Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73–96, 1994.

Goncalves E. , da Costa L. , Abigerges D. , Armand J.P. : A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J. Clin. Oncol., 13: 2144–2146, 1995.

Giovanella B.C. , Stehlin J.S. , Wall M.E. , Wani M.C. , Nicholas A.W. , Liv L.F. , Silber R. , Postmesil M. : DNA topo-isomerase I targeted chemotherapy of human colon cancer in xenografts. Science, 246: 1046–1048, 1989.

Hagipantelli R. , Saliba F. , Misset J.L. , Giacchetti S. , Brain E. , Bertheault-Cvitkovic F. , Vassal G. , Bonnay M. , Bastian G. , Cote C. , Mahajoubi M. , Heirat P. , Cvitkovic E. : Pathophysiology and therapy of irinotecan (CPT-11) induced delayed diarrhea (DD). A prospective assessment. Proc. Am. Soc. Clin. Oncol., 1995 May 20–23, Los Angeles, California, USA.

Hsiang Y.H. , Lihou M.G. , Liu L.F. : Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077–5082, 1989.

Pitot H.C. , Wender D. , O'Connell M.J. , Wicand H.S. , Mail-land J.A. : A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. 30th Annual Meeting of the Am. Soc. Clin. Oncol., Dallas, Texas. May 14–17, 1994: 573.

Rougier P. , Bugat R. , Brunet P. : Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer (CRC): results of a multicentric open phase II study (abstract). 5th International Congress of Anti-Cancer Chemotherapy, Paris, France. Jan/Feb 31–3, 1995: S775.

Shimada Y. , Masahiro Y. , Akiro W. , Isao N. , Koichi F. , Yuh S. , Mariko K. , Tetsuo T. , Nobuye O. : Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909–913, 1993.

Van Cutsem E. , Cunningham D. , Ten Bokkel Huinink W. : Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5FU: preliminary results. Proc. Am. Soc. Clin. Oncol., 15: 230, 1996.

Van Cutsem E. , Rougier Ph. , Droz J.P. , Marty M. , Bleiberg H. : Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc. Am. Soc. Clin. Oncol., 1997, 16.